Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 46

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 46
---
 to design appropriate clinical trial protocols;                                                                                         |
| ● | insufficient                                                                                                                            
 data to support regulatory approval;                                                                                                    |
| ● | inability                                                                                                                               
 or unwillingness of medical investigators to follow our clinical protocols; or                                                          |
| ● | difficulty                                                                                                                              
 in maintaining contact with patients during or after treatment, which may result in incomplete data.                                    |

Any of the foregoing could have a material adverse effect on TELO’s business, results of operations and financial condition.

Risks Related to Interested Parties and Conflicts of Interests

TELI’s directors and executive officers and TELO’s directors and officers have interests in the Merger that may be different from, or in addition to, the interests of TELI stockholders generally and the interests of TELO stockholders generally.

Certain TELI directors and executive officers have interests in the Merger that may be different from, or in addition to, those of TELI stockholders. Certain of TELI’s directors and executive officers negotiated the terms of the Merger Agreement and some of them hold executive positions in TELO. Further, certain of the stockholders of TELO also hold shares of TELI Common Stock, and certain of such directors and officers may also serve as directors or officers of companies with whom TELI has ongoing contractual relations. For example, TELO’s Chief Executive Officer, Erez Aminov, and owner of 6,411,200 shares of TELO also holds a beneficial ownership interest of 12,169,710 shares, or 25.02%, on a fully diluted basis, of TELI. Furthermore, shares of TELI are held by several trusts or individuals, also own shares of TELO. Specifically, (i) Bayshore Trust, holders of 5,406,431 shares of TELO, on a fully diluted basis, hold 20,798,767 shares of TELI, or 42.67% on a fully diluted basis, and (ii) the Celeste J Williams Lifetime QTIP Trust holds of 1,853,659 shares of TELI and 1,000,000, or 2.6% shares of TELI. Some of such relations may create conflicts with the interests of TELI or TELO. For example, certain beneficial shareholders of TELI and of TELO are owners of MIRALOGX, the licensor to TELI and TELO of Telomir-1. In some cases,